Compare MSGE & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGE | TNGX |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.1B |
| IPO Year | 2023 | 2020 |
| Metric | MSGE | TNGX |
|---|---|---|
| Price | $79.51 | $24.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $91.63 | $45.18 |
| AVG Volume (30 Days) | 348.5K | ★ 2.5M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.22 | 26.89 |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $942,734,000.00 | $62,384,000.00 |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $4.62 | N/A |
| P/E Ratio | $60.57 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $41.65 | $6.69 |
| 52 Week High | $90.41 | $34.39 |
| Indicator | MSGE | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 55.12 |
| Support Level | $74.65 | $19.74 |
| Resistance Level | $82.79 | $26.05 |
| Average True Range (ATR) | 2.65 | 1.53 |
| MACD | 0.08 | 0.29 |
| Stochastic Oscillator | 34.83 | 85.77 |
Madison Square Garden Entertainment Corp provides live entertainment, delivering unforgettable experiences while forging deep connections with diverse and passionate audiences. The company's portfolio includes a collection of world-renowned venues - New York's Madison Square Garden, The Theater at Madison Square Garden, Radio City Music Hall, and Beacon Theatre; and The Chicago Theatre - that showcase a broad array of sporting events, concerts, family shows, and special events for millions of guests annually. In addition, the company features the original production, the Christmas Spectacular Starring the Radio City Rockettes, which has been a holiday tradition for 89 years.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.